Cancer Patients Rehabilitation Rally is Underway!

Cancer Patients Rehabilitation Rally is Underway!

On April 20, 2025, the "Beyond Limits" Cancer Patients Rehabilitation Rally was officially launched across China. Organized by the Cancer Rehabilitation Society of CACA , and supported by Hengrui Pharmaceuticals, the initiative harnesses digitization and other cutting-edge technologies to enhance long-term survival rates and quality of life for cancer patients.
Do we need a change in surgical antimicrobial prophylaxis? Insights from Dr. Camilla Rodrigues

Do we need a change in surgical antimicrobial prophylaxis? Insights from Dr. Camilla Rodrigues

Antimicrobial resistance (AMR) continues to pose a serious threat to global health systems, particularly in high-burden countries like India. The challenges it presents to surgical treatment are complex and evolving, demanding both robust surveillance and strategic preventive interventions. In this interview, Dr. Camilla Rodrigues from Hinduja Hospital shares the current epidemiological landscape of AMR in India, discusses the risks it poses to surgical patients, and outlines successful approaches her center has implemented to mitigate these threats—particularly through systematic MRSA decolonization and strengthened infection control protocols.
CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, introduced significant updates to the 2025 edition of the CSCO Breast Cancer Guidelines (CSCO BC Guidelines). Among the most notable changes was a revision in the treatment approach for patients with HER2-low breast cancer. Oncology Frontier invited Professor Ying Yan from Beijing Cancer Hospital to provide insights into the new treatment strategies for HER2-low and HER2 ultra-low breast cancer.
NCCN 2025 | Professor Jihong Liu: Strengthening Management and Monitoring Adverse Events in Immunotherapy-Chemotherapy for Endometrial Cancer

NCCN 2025 | Professor Jihong Liu: Strengthening Management and Monitoring Adverse Events in Immunotherapy-Chemotherapy for Endometrial Cancer

Endometrial cancer is one of the most common gynecologic malignancies, with its global incidence on the rise. In recent years, immunotherapy combined with chemotherapy has emerged as a promising strategy, demonstrating significant benefits in prolonging survival and maintaining durable responses in patients with advanced or recurrent endometrial cancer. However, as the use of immuno-chemotherapy becomes more widespread, concerns surrounding its safety profile have also come to the forefront.